Dr Chahoud on ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma

“These patients [can receive ALLO-316] and go on without any therapy, they just need to be monitored with repeat scans. [The long-term responders] are a sign that these CAR [T-cell therapies] do a good, long-lasting job.”

Jad Chahoud, MD, MPH, an associate member of the Department of Genitourinary Oncology and medical director of IPOP at Moffitt Cancer Center, discussed efficacy data with the off-the-shelf, HLA-unmatched, CD70 CAR T-cell therapy ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma (ccRCC).

During the 2025 ASCO Annual Meeting, investigators presented data from the phase 1 TRAVERSE study (NCT04696731), which examined ALLO-316 in patients with CD70-positive ccRCC who experienced disease progression after PD-1 axis and VEGF-targeted therapies. The patient population was heavily pretreated, with a median of 4 (range, 1-11) prior lines of therapy.

Findings from TRAVERSE revealed that patients with a CD70 tumor proportion score (TPS) of at least 50% who received ALLO-316 in phase 1a or 1b experienced a confirmed overall response rate (ORR) of 26% (n = 8/31), Chahoud said. Additionally, the confirmed ORR among patients treated in phase 1b with a CD70 TPS of at least 50% (n = 16) was 31%, he added. Forty-four percent of patients with a CD70 TPS of at least 50% treated in phase 1b experienced a reduction of over 30% in the diameter of baseline targeted lesions, he noted.

Regarding response duration, 1 patient out of 5 confirmed responders has remained in response for more than 1 year as of the May 2, 2025, data cutoff, Chahoud said. There are 2 additional patients who have been in response for 7 and 9 months, respectively, he added. Chahoud noted that patients can receive ALLO-316 as a one-time infusion and can continue without treatment while being monitored with repeat scans.